Ovid Therapeutics (OVID) Shares Outstanding (Diluted Average) (2020 - 2026)

Ovid Therapeutics has reported Shares Outstanding (Diluted Average) for 7 years, with the latest figure at $136.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 10893611.44% year-over-year to $136.2 million; the trailing twelve-month figure through Mar 2026 stood at $136.2 million (up 10893611.44% YoY), and the FY2025 full-year result was $73.7 million, up 5898748.48% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $136.2 million, up from $73.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $136.2 million in Q1 2026, with the low at $1250.0 in Q4 2023.
• Historically, Shares Outstanding (Diluted Average) has averaged $58.1 million across 5 years, with a median of $70.5 million in 2023.
• Annual changes were most pronounced in 2025 — Shares Outstanding (Diluted Average) slumped 100.0% — and 2026, when it surged 10893611.44%.
• Ovid Therapeutics' Shares Outstanding (Diluted Average) stood at $70.4 million in 2022, then tumbled by 100.0% to $1250.0 in 2023, then changed by 0.0% to $1250.0 in 2024, then surged by 5898748.48% to $73.7 million in 2025, then soared by 84.68% to $136.2 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $136.2 million (Q1 2026), $73.7 million (Q4 2025), and $71.1 million (Q3 2025), per Business Quant data.